How Many FOXs Are There on The Road to Pulmonary Hypertension?
The Fox (forkhead box) proteins belong to a large family of evolutionary conserved transcription factors (TFs) in the winged helix/forkhead DNA-binding domain. The Fox family includes more than 55 distinct mammalian members grouped into 19 subfamilies (FoxA-FoxS) according to their sequence homology within the DNA-binding domain. Although all Fox proteins share this unique DNA-binding domain, distinct protein domains apart from conserved DNA-binding domain, expression patterns, and post-translational modifications contribute to the divergent functions of Fox family members. The Fox proteins regulate a wide spectrum of biological processes including cell proliferation, apoptosis, differentiation, and resistance to DNA damage (1) . As a consequence, either a loss or gain of Fox function can alter cell fate and promote various human pathologies including cancer and cardiovascular diseases. The best-studied Fox proteins involved in the above-mentioned pathologies are FoxM, FoxO, and FoxP (1).
Among these, FoxM1 is crucial for G1-S and G2-M cell cycle phase progression and mitotic spindle integrity. FoxM1 is highly expressed in proliferating cells including embryonic tissues, adult tissues that have high proliferation index (2) , and all solid tumors (3). In contrast, activation of the FoxO family of proteins (FoxO1, FoxO3A, FoxO4, and FoxO6) is associated with cell cycle arrest and the induction of apoptosis (4), and thus, the function of FoxO proteins is often reduced in proliferating cells.
Accumulating evidence suggests that Fox subfamilies FoxM1 and FoxOs are correlated with various biological processes associated with the development of pulmonary hypertension (PH), such as PH initiation and progression. This editorial highlights the complex regulatory mechanisms of FoxM1 and FoxOs in PH, their critical roles in the pathogenesis of PH, their potential as therapeutic targets, and questions remaining to be addressed concerning these issues. Increased FoxM1 levels and activity result in smooth muscle cell proliferation, apoptosis resistance, and genome stability by activating genes involved in cell proliferation, antiapoptosis, and DNA repair. CR = cytokine receptor; CXCL12 = chemokine ligand 12; ET-1 = endothelin-1; ETR = endothelin receptor; GFR = growth factor receptor; IGF-1 = insulin-like growth factor-1; Mf = macrophage; MIF = macrophage migration inhibitory factor; NBS1 = Nijmegen breakage syndrome 1; PDGF-BB = platelet-derived growth factor-BB; TNF-a = tumor necrosis factor-a.
Pulmonary hypertension (PH) is a deadly disease characterized by vasoconstriction and abnormal remodeling of pulmonary vessels, leading to a progressive increase in pulmonary artery pressure, which culminates in right ventricular failure and premature death (5) . Observations across species and animal models have demonstrated that numerous stimuli and pathologic conditions (sheer stress, hypoxia, oxidative stress, infection, and others) can cause deregulation of normal cellular processes in the pulmonary vasculature, which culminates in abnormalities in proliferation, differentiation, inflammation, and cell death programs, which all together contribute to the development of PH. The initiation process can involve a variety of growth factor, integrin, cytokine, and other ligands, which initiate different signaling cascades, ultimately converging on a common program targeting the activity of certain TFs. Multiple TFs have been implicated in PH development (6) . In this issue of the Journal, Dai and colleagues (pp. 788-802) identify another TF, FoxM1, as playing a key role in PH development (7) . They demonstrate that FoxM1 is markedly upregulated in the lungs of patients with idiopathic pulmonary arterial hypertension (PAH) and various rodent models of PH. These observations are consistent with another recently published manuscript by Bourgeois and colleagues, also demonstrating that FoxM1 is overexpressed in pulmonary artery smooth muscle cells (SMCs) from patients with idiopathic PAH (8). In elegant genetic disruption studies, the authors found that deletion of FoxM1 in SMCs, but not in endothelial cells, in mice protects from hypoxia or sugen/hypoxia-induced PH. Similarly, there is also ample evidence implicating FoxOs, mainly FoxO1 isoform, in PH. Indeed, targeted depletion of FoxO1 specifically in SMCs, both in vitro and in vivo, is sufficient to induce pulmonary vascular remodeling and PH and also synergizes with the hypertensive effects of hypoxia, resulting in more severe PH (9) and suggesting a causative role of SMC FoxO1 in PH (9) (Figure 1 ).
Open Questions and Remaining Challenges
Is FoxM1 a critical integrator of multiple signaling pathways driving PH? Dai and colleagues demonstrate that endothelial-derived factors such as CXCL12, PDGFb, ET-1, and MIF are capable of inducing FoxM1 expression in SMCs and of causing SMC proliferation in a FoxM1-dependent manner (7) . In addition to the apparent direct stimulatory effects of cytokines and growth factors on FoxM1 gene transcription are findings demonstrating the epigenetic-and TF-mediated regulation of FoxM1. Raghavan and colleagues demonstrated that hypoxia induces FoxM1 gene expression via HIF-2a, whereas Bourgeois and colleagues demonstrated miR-204-mediated regulation of FoxM1 in pulmonary artery SMCs (8, 10) . Further, it has been shown that growth factors and cytokines, which are activated in patients with PH, lead to activation of AKT or JNKs, which then leads to the phosphorylation and nuclear exclusion of FoxOs, and thus upregulation of FoxM1 (9) (Figure 1 ). Although this study shows a role for endothelial-derived factors in controlling FoxM1 production, it is clear that other cell-cell interactions in the vessel wall may also regulate SMC FoxM1 expression. Future studies should evaluate the role of FoxM1 in inflammatory cells and fibroblasts, as well as the interactions between these cells and SMCs (Figure 1) .
What are the consequences of FoxM1 deregulation? Dai and colleagues showed that FoxM1 upregulation leads to SMC hyperproliferation, and subsequently vascular remodeling. In addition, Bourgeois and colleagues showed that FoxM1 deficiency reduces resistance to apoptosis through diminished DNA repair mechanisms and increased survivin expression (8) . Recent studies suggest mitochondrial, metabolic, and inflammatory remodeling as critical pathogenetic components of PH (11) . FoxM1 being a target gene of FoxOs (major metabolic regulators among the Fox family members) (12) , as well as an interacting partner of various TFs, such as NFkB, b-catenin, and STAT3, suggests a better understanding of the regulation of FoxM1 in the abovementioned remodeling processes could provide interesting insights into PH development. Identification of FoxM1-FoxO axis target genes and gene networks in PH vascular cells will be very important.
Is FoxM1 a potential therapeutic target for PH? The studies from both Dai and Bourgeois demonstrate that inhibition of FoxM1 with thiostrepton significantly improved established PH in both hypoxia1SU5416 and monocrotaline-challenged rats. Furthermore, FoxO activators or HDAC (histone deacetylase) inhibitors can indirectly target FoxM1. It may be that the beneficial effects of FoxM1 inhibition in vivo are the result of a cumulative effect on numerous signaling pathways. Because of the critical role of FoxM1 in normal cell proliferation, maintenance of genome stability, and DNA damage repair, it will be essential to specifically deliver FoxM1 inhibitors to the pulmonary vasculature to reduce/avoid the potential adverse effect of loss of FoxM1 activity in proliferating normal cells.
Conclusions
FoxM1 is implicated in SMC proliferation, which contributes to pulmonary vascular remodeling and PH. Thus, targeting FoxM1 signaling represents a novel strategy for treatment of PAH. However, a deeper understanding of the upstream and downstream molecular mechanisms mediating FoxM1 control of PH (e.g., FoxM1 regulation and role in different subgroups of PH, the mechanisms driving FoxM1 regulation, and the molecular and cellular effects driven by FoxM1 in PH-vascular cells) is essential for developing tailored therapeutic concepts focusing on FoxM1 inhibition. n Nearly 45 years ago, Suga and colleagues (1) proposed a new approach for quantifying heart pump function based on the concept of elastance or elasticity. Elasticity is a material property that describes how much stress is required to cause material deformation. To illustrate, if the ventricle is a balloon, its elasticity can be measured by how much air (or blood) pressure is required to cause an increase in volume. Unlike a balloon that has constant material properties, a ventricle has time-changing material properties. During filling, the ventricle has a low elasticity, which enables a large increase in volume for a small increase in pressure; during isovolumic contraction, the elasticity increases such that ventricular pressure increases, even though there is no change in volume. Then, during ejection and isovolumic relaxation, elasticity increases and decreases to its diastolic value. One benefit of the time-varying elasticity, or elastance, is that it can be measured from pressure-volume loops. A second is that it is load independent for the left ventricle (1), as well as the right ventricle (2).
Building on the concept of ventricular time-varying elastance, but turning attention toward the problem of the "interaction between the right heart ventricle and its arterial load" (3), Hroar Piene proposed that ventricular elastance should match or couple to the opposition to pulsatile flow in the pulmonary vasculature when "a linkage exists between their two structures"; that is, during systole. Unfortunately, he could not arrive at an analytical solution because the time-varying opposition to flow, or impedance, was computed from a graphical analysis of pressure and flow waves at the time. A year later, Sunagawa and others showed that matching end-systolic elastance (Ees), measured from the ratio of end-systolic pressure to end-systolic volume over multiple heart beats with varying preload, to arterial elastance at end systole (Ea), calculated as end-systolic pressure divided by stroke volume, was a simple and robust approach for assessing ventricular-vascular or ventriculoarterial interactions (or ventricular-vascular coupling) (4).
This new concept found broader use with the development of estimates of Ees based on a single heartbeat instead of multiple beats with varying preload. This "single-beat" method was first developed by Sunagawa and colleagues and validated for the left ventricle, using data from healthy dogs and humans (5, 6) , and then validated for the right ventricle using data from healthy dogs (7) .
Fast forward to today, and an informal survey of PubMed using search terms such as ("right ventricle" AND "pulmonary 
